Evaluation of Prognostic Factors in Patients with Relapse and Unresectable Biliary Tract Cancer, Treated with S-1 after Failure of Gemcitabine-Reference-Cited by-同舟云学术

Evaluation of Prognostic Factors in Patients with Relapse and Unresectable Biliary Tract Cancer, Treated with S-1 after Failure of Gemcitabine

Published:2022-09-01 Issue:9 Volume:142 Page:1021-1029
ISSN:0031-6903
Container-title:YAKUGAKU ZASSHI
language:en
Short-container-title:YAKUGAKU ZASSHI

Author:

Nakai Masato¹,Kikkawa Akiyoshi²,Funahara Hiroko¹,Matsumoto Shunji¹,Hiraki Koichi³

Affiliation:

1. Department of Pharmacy, Hiroshima City Hiroshima Citizens Hospital

2. Department of Pharmacy, Hiroshima City Funairi Citizens Hospital

3. Hiroshima City Hospital Organization

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/yakushi/142/9/142_21-00231/_pdf

Reference25 articles.

1. 1) Center for Cancer Control and Information Services National Cancer Center. “Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan, Ministry of Health, Labour and Welfare).”: 〈https://ganjoho.jp/reg_stat/statistics/dl/index.html〉, cited 13 June, 2021.

2. 2) Valle J., Wasan H., Palmer D. H., Cunningham D., Anthoney A., Maraveyas A., Madhusudan S., Iveson T., Hughes S., Pereira S. P., Roughton M., Bridgewater J., N. Engl. J. Med., 362, 1273-1281 (2010).

3. 3) Morizane C., Okusaka T., Mizusawa J., et al., members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG), Ann. Oncol., 30, 1950-1958 (2019).

4. 4) Japanese Society of Hepato-Biliary-Pancreatic Surgery, “Clinical Practice Guidelines for the Management of Biliary Tract Cancers, The 3rd Edition,” Igakutosho-shuppan Ltd., Tokyo, pp. 114-116.

5. 5) Kobayashi S., Ueno M., Ohkawa S., Andou T., Kameda R., Yamamoto N., Morinaga S., Jpn. J. Clin. Oncol., 42, 800-806 (2012).